Here’s the latest FDA treatment for wet macular degeneration. Here’s why it’s unique!
The post Beovu for Wet Macular Degeneration appeared first on Retina Specialist | Fairfax, Virginia | Retinal Diseases.
Tag: anti-VEGF
New Treatments for Diabetic Macular Edema | Diabetic Retinopathy
Over the past 2 years, several new treatments have become FDA approved for treating diabetic retinopathy!
Submacular hemorrhages may be managed with anti-VEGF
WAIKOLOA, Hawaii — Intravitreal injections may successfully help manage submacular hemorrhages, according to a speaker here.“We know that submacular hemorrhages have a significant variability in their clinical course,” Mark W. Johnson, MD, said at Retina 2013. “But it does seem that poor prognostic factors include thick blood under the fovea and the presence of AMD. And we know that when an eye has both of these factors, the final visual outcome if you don’t treat these is rarely better than 20/200.”
Further data for aflibercept in neovascular age-related macular degeneration
Source: BioSpace
Area: News
BioSpace has reported on the results of an integrated analysis of two Phase III studies (VIEW 1 and VIEW 2) of aflibercept intravitreal injection in the treatment of neovascular age-related macular degeneration (wet AMD).&…
VEGF-Trap Gets Closer to FDA Approval
VEGF-Trap (aka aflibercept), another anti-VEGF drug, moves closer to FDA approval as it received priority review status. This status means that the FDA process will be accelerated and the drug can be reviewed in 6 months versus the usual 10…
CATT Study Update 12: Status of WorldWide Studies
With the anticipated arrival of the one-year results of the CATT Study this Spring, I thought it would be appropriate to update where the other worldwide studies stand.During the Retina Subspecialty Day sessions, held prior to the recent 2010 AAO Meeti…
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in CRVO and in Phase 2 Study in DME
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with m…
Avastin/Lucentis Update 44: United Kingdom Closer to Allowing Avastin for AMD
While the U.S. comes closer to showing the equivalency of Avastin to Lucentis for treating the wet form of age-related macular degeneration, when the CATT Study (Comparisons of Age-Related Macular Degeneration Treatments Trials) results become public, …
Bevacizumab vs Ranibizumab for Age-related Macular Degeneration: 1-year Outcomes of a Prospective, Double-masked Randomised Clinical Trial
This study compares two drugs in the treatment of age-related macular degeneration. Eye
How Effective Are AMD Drugs in Treating Diabetic Macular Edema?
At the AAO meeting in October, researchers reported that anti-VEGF drugs such as ranibizumab (Lucentis) and pegaptanib (Macugen) also appeared to be effective in improving visual acuity in patients with diabetic macular edema in a series of randomized, controlled trials. Full…
Cochrane Review Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion
Central retinal vein occlusion (CRVO) is a common retinal vascular disorder in which macular edema (ME) may develop, with a consequent reduction in visual acuity. The visual prognosis in CRVO-ME is poor in a substantial proportion of patients, especial…
Lucentis receive DME approval in EU
(Ophtalmology Times Europe) Novartis has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its therapy Lucentis for the treatment of patients with diabetic macular oedema (DME). Full Story ->
Avastin Intravitreal Bevacizumab Genentech Inc for treatment of choroidal neovascularization secondary to pathological myopia
New abstract in the Health Technology Assessment (HTA) Database from the Centre for Reviews and Dissemination.
Do Anti-VEGF Injections Increase the Risk of Stroke or Heart Attack?
By Dr. Ari WeitznerSome have speculated that the anti-VEGF injections we give to macular degeneration patients may get into the bloodstream and have adverse vascular effects. According to a recently released retrospective study (appearing in the October 2010 issue of the Archives of Ophthalmology), using vascular endothelial growth factor (VEGF) blockers to treat neovascular age-related […]
Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion
New Cochrane review issued on 6th October 2010.